Boston Scientific (BSX) Stock Price, News & Analysis

Company Overview

Boston Scientific Corporation, founded in 1979 and headquartered in Marlborough, Massachusetts, is a global developer, manufacturer, and marketer of medical devices designed to diagnose and treat a broad range of cardiovascular, respiratory, digestive and urological conditions. Over more than four decades, the company has built a reputation for innovation in minimally invasive therapies, enabling physicians and healthcare providers to deliver advanced care to patients around the world.

The company’s core product portfolio spans interventional cardiology, electrophysiology, peripheral interventions, endoscopy, urology and neuromodulation. In cardiovascular care, Boston Scientific offers drug-eluting stents, pacemakers and implantable cardioverter-defibrillators, along with diagnostic catheters and balloons for angioplasty. Its endoscopy range includes advanced imaging systems and biopsy tools for gastrointestinal procedures, while urology products feature lithotripsy devices and implantable stents for the treatment of urinary strictures. The neuromodulation business provides spinal cord stimulation systems for chronic pain management, as well as implants for movement and pelvic health disorders.

With operations in more than 130 countries, Boston Scientific serves hospitals, outpatient clinics and physician offices across the Americas, Europe, the Middle East, Africa and the Asia-Pacific region. The company maintains research and development centers in North America and Europe, with additional manufacturing facilities in Ireland, Costa Rica and India. This global footprint supports collaboration with leading clinicians and academic institutions to advance clinical research and product innovation.

Leadership at Boston Scientific is headed by President and Chief Executive Officer Robert S. Ford, who brings extensive industry experience and a focus on strategic growth and operational excellence. The company’s commitment to cutting-edge technology is evidenced by a series of strategic acquisitions over the years, which have expanded its therapeutic offerings and strengthened its position in key markets. Through continual investment in R&D and a drive to improve patient outcomes, Boston Scientific aims to deliver enduring value to healthcare professionals and patients worldwide.

Key Stats

• Today's Range: $103.48 to $104.50
• 50-Day Range: $98.43 to $107.45
• 52-Week Range: $71.88 to $107.53
• Volume: 2.93 million shs
• Average Volume: 6.64 million shs
• Market Capitalization: $154.30 billion
• P/E Ratio: 76.13
• Dividend Yield: N/A
• Price Target: $116.09
• Consensus Rating: Buy

Boston Scientific Stock Analysis - MarketRank™

Boston Scientific scored higher than 93% of companies evaluated by MarketBeat, and ranked 76th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Boston Scientific has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 21 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Boston Scientific has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 13.33%

Earnings Growth

Earnings for Boston Scientific are expected to grow by 13.33% in the coming year, from $2.85 to $3.23 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Boston Scientific is 76.13, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.78.

Price to Earnings Ratio vs. Sector

The P/E ratio of Boston Scientific is 76.13, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.75.

Price to Earnings Growth Ratio

Boston Scientific has a PEG Ratio of 2.71. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Boston Scientific has a P/B Ratio of 6.99. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.19% of the float of Boston Scientific has been sold short.

Short Interest Ratio / Days to Cover

Boston Scientific has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Boston Scientific has recently increased by 2.76%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Boston Scientific does not currently pay a dividend.

Dividend Growth

Boston Scientific does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.2 / 5
• Environmental Score: -1.02

Percentage of Shares Shorted

1.19% of the float of Boston Scientific has been sold short.

Short Interest Ratio / Days to Cover

Boston Scientific has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Boston Scientific has recently increased by 2.76%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.37

News Sentiment

Boston Scientific has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 61 news articles for Boston Scientific this week, compared to 28 articles on an average week.

Search Interest

37 people have searched for BSX on MarketBeat in the last 30 days. This is an increase of 19% compared to the previous 30 days.

MarketBeat Follows

18 people have added Boston Scientific to their MarketBeat watchlist in the last 30 days. This is an increase of 29% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Boston Scientific insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $47,755,193.00 in company stock.

Percentage Held by Insiders

Only 0.50% of the stock of Boston Scientific is held by insiders.

Percentage Held by Institutions

89.07% of the stock of Boston Scientific is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

BSX Stock Analysis - Frequently Asked Questions

How have BSX shares performed this year?

Boston Scientific's stock was trading at $89.32 on January 1st, 2025. Since then, BSX shares have increased by 16.8% and is now trading at $104.2950.

How were Boston Scientific's earnings last quarter?

Boston Scientific Corporation (NYSE:BSX) posted its quarterly earnings data on Wednesday, April, 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.08. The business's revenue for the quarter was up 20.9% on a year-over-year basis.
Read the conference call transcript.

Does Boston Scientific have any subsidiaries?

Boston Scientific subsidiaries include VertiFlex, BTG, Augmenix, Veniti, Claret Medical, Cryterion Medical, nVision Medical, and more.

Who are Boston Scientific's major shareholders?

Boston Scientific's top institutional investors include Legacy Wealth Management LLC MS, Neville Rodie & Shaw Inc., Central Pacific Bank Trust Division and Arvest Investments Inc.. Insiders that own company stock include Michael F Mahoney, Daniel J Brennan, Joseph Michael Fitzgerald, Vance R Brown, Jonathan Monson, Eric Francis Yves Thepaut, Wendy Carruthers, Jeffrey B Mirviss, Nelda J Connors, Edward J Ludwig, Edward J Ludwig, Arthur C Butcher, John Bradley Sorenson and Charles J Dockendorff.
View institutional ownership trends.

How do I buy shares of Boston Scientific?

Shares of BSX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Boston Scientific own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Boston Scientific investors own include BlackRock (BLK), Broadcom (AVGO), ServiceNow (NOW), UnitedHealth Group (UNH), The Goldman Sachs Group (GS), NVIDIA (NVDA) and Illinois Tool Works (ITW).

Company Calendar

• Last Earnings: 4/23/2025
• Today: 7/07/2025
• Next Earnings (Estimated): 7/23/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Health Care Equipment
• Current Symbol: NYSE:BSX
• CIK: 885725
• Web: www.bostonscientific.com
• Phone: (508) 683-4000
• Fax: 508-683-5675
• Employees: 53,000
• Year Founded: 1979

Price Target and Rating

• Average Stock Price Target: $116.09
• High Stock Price Target: $130.00
• Low Stock Price Target: $100.00
• Potential Upside/Downside: +11.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.13
• Research Coverage: 24 Analysts

Profitability

• EPS (Trailing Twelve Months): $1.37
• Trailing P/E Ratio: 76.13
• Forward P/E Ratio: 36.59
• P/E Growth: 2.71
• Net Income: $1.85 billion
• Net Margins: 11.58%
• Pretax Margin: 14.12%
• Return on Equity: 18.67%
• Return on Assets: 10.38%

Debt

• Debt-to-Equity Ratio: 0.47
• Current Ratio: 1.45
• Quick Ratio: 0.88

Sales & Book Value

• Annual Sales: $16.75 billion
• Price / Sales: 9.21
• Cash Flow: $3.65 per share
• Price / Cash Flow: 28.58
• Book Value: $14.93 per share
• Price / Book: 6.99

Miscellaneous

• Outstanding Shares: 1,479,450,000
• Free Float: 1,472,049,000
• Market Cap: $154.30 billion
• Optionable: Optionable
• Beta: 0.68